{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:04:38Z","timestamp":1790060678293,"version":"4.0.1"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The number of patients maintained on buprenorphine is steadily increasing. To date, no study has reported buprenorphine management practices for these patients during critical illness, nor its relationship with supplemental full\u2010agonist opioid administration during their hospital stay. In this single\u2010center retrospective study, we have explored the incidence of buprenorphine continuation during critical illness among patients receiving buprenorphine for the treatment of opioid use disorder. Additionally, we investigated the relationship between nonbuprenorphine opioid exposure and buprenorphine administration during the intensive care unit (ICU) and post\u2010ICU phases of care. Our study included adults maintained on buprenorphine for opioid use disorder admitted to the ICU between December 1, 2014, and May 31, 2019. Nonbuprenorphine, full agonist opioid doses were converted to fentanyl equivalents (FEs). Fifty\u2010one (44%) patients received buprenorphine during the ICU phase of care, with an average dose of 8 (8\u201312) mg\/day. During the post\u2010ICU phase of care, 68 (62%) received buprenorphine, with an average dose of 10 (7\u201314) mg\/day. Lack of mechanical ventilation and acetaminophen use were also associated with buprenorphine use. Full agonist opioid use was more frequent on days when buprenorphine was not given (odds ratio [OR], 6.2 [95% CI, 2.3\u201316.4]; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001). Additionally, the average cumulative dose of opioids given on nonbuprenorphine administration days was significantly higher both in the ICU (OR, 1803 [95% CI, 1271\u20132553] vs OR, 327 [95% CI, 152\u2013708] FEs\/day; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a00.001) and after ICU discharge (OR, 1476 [95% CI, 962\u20132265] vs OR, 238 [95% CI, 150\u2010377] FEs\/day; <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001). Given these findings, buprenorphine continuation during critical illness should be considered, as it is associated with significantly decreased full agonist opioid use.<\/jats:p>","DOI":"10.1002\/jcph.2286","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T14:24:22Z","timestamp":1684506262000},"page":"1067-1073","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Buprenorphine Continuation During Critical Illness Associated With Decreased Inpatient Opioid Use in Individuals Maintained on Buprenorphine for Opioid Use Disorder in a Retrospective Study"],"prefix":"10.1002","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7573-2164","authenticated-orcid":false,"given":"Aurora","family":"Quaye","sequence":"first","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine Maine Medical Center  Portland ME USA"},{"name":"Spectrum Healthcare Partners  South Portland ME USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Wampole","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Maine Medical Center  Portland ME USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Riker","sequence":"additional","affiliation":[{"name":"Department of Critical Care Services Maine Medical Center  Portland ME USA"},{"name":"Tufts University School of Medicine  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Seder","sequence":"additional","affiliation":[{"name":"Department of Critical Care Services Maine Medical Center  Portland ME USA"},{"name":"Tufts University School of Medicine  Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4322-9043","authenticated-orcid":false,"given":"William J.","family":"Sauer","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine Maine Medical Center  Portland ME USA"},{"name":"Spectrum Healthcare Partners  South Portland ME USA"},{"name":"Department of Critical Care Services Maine Medical Center  Portland ME USA"},{"name":"Department of Anesthesiology Montefiore Medical Center and Albert Einstein College of Medicine  Bronx NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle M.","family":"Richard","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine Maine Medical Center  Portland ME USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Y.","family":"Craig","sequence":"additional","affiliation":[{"name":"MaineHealth Institute for Research  Scarborough ME USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Gagnon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Maine Medical Center  Portland ME USA"},{"name":"Tufts University School of Medicine  Boston MA USA"},{"name":"MaineHealth Institute for Research  Scarborough ME USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"National Institute on Drug Abuse.Effective treatments for opioid addiction.2016.https:\/\/nida.nih.gov\/publications\/effective\u2010treatments\u2010opioid\u2010addiction. Accessed February 6 2023."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1604339"},{"key":"e_1_2_9_4_1","unstructured":"Substance Abuse and Mental Health Services Administration.National survey of substance abuse treatment services: 2020. Data on substance abuse treatment facilities.2021.https:\/\/www.samhsa.gov\/data\/report\/national\u2010survey\u2010substance\u2010abuse\u2010treatment\u2010services\u2010n\u2010ssats\u20102020\u2010data\u2010substance\u2010abuse. Accessed February 6 2023."},{"key":"e_1_2_9_5_1","unstructured":"Maine Health Data Organization.Prescription drug costs and utilization in maine at retail and mail order pharmacies.2019.https:\/\/mhdo.maine.gov\/tableau\/prescriptionReports.cshtml. Accessed February 6 2023."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2019.06.032"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1999"},{"key":"e_1_2_9_8_1","unstructured":"Substance Abuse and Mental Health Services Administration.Medications for opioid use disorder.Treatment Improvement Protocol (TIP) Series 63 Publication No. PEP21\u201002\u201001\u2010002.2020.https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP21\u201002\u201001\u2010002.pdf. Accessed March 10 2022."},{"issue":"1","key":"e_1_2_9_9_1","first-page":"E1","article-title":"Buprenorphine formulations: clinical best practice strategies recommendations for perioperative management of patients undergoing surgical or interventional pain procedures","volume":"21","author":"Jonan AB","year":"2018","journal-title":"Pain Physician"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-2-200601170-00010"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6105.1000146"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000003299"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000735"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0885066620933798"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2016.09.006"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pny217"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12630-018-1255-3"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pny019"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.10.007"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/rapm-2021-103007"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.2286","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T12:22:39Z","timestamp":1694089359000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.2286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/jcph.2286"],"URL":"https:\/\/doi.org\/10.1002\/jcph.2286","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"2023-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}